Literature DB >> 24952900

Nicorandil suppresses urinary protein excretion and activates eNOS in Dahl salt-sensitive hypertensive rats.

Yoshihito Tashiro1, Kenji Yogo2, Kenichi Serizawa1, Koichi Endo1.   

Abstract

BACKGROUND: Hypertension is a risk factor common to both chronic kidney disease and cardiovascular disease. Nicorandil is widely used for the treatment of angina. We investigated the benefits of nicorandil with respect to renal dysfunction in Dahl salt-sensitive hypertensive (DS) rats.
METHOD: DS rats were fed a high-salt (HS) diet and nicorandil was administered via the drinking water. Blood pressure and renal function were measured for 4 weeks after starting the rats on the HS diet.
RESULTS: In rats fed the HS diet, renal dysfunction was manifested by an increase in urinary protein and N-acetyl-β-D-glucosaminidase excretion. Nicorandil ameliorated renal function with a concomitant reduction in urinary 8-hydroxy-2'-deoxyguanosine and an increase in urinary NOx. Significant upregulation of endothelial nitric oxide synthase (eNOS) expression and an increase in the eNOS dimer/monomer ratio (reduction of eNOS uncoupling) was demonstrated in glomeruli following nicorandil treatment. The blood pressure of DS rats was increased by salt loading; however, no significant change in blood pressure was observed with nicorandil treatment.
CONCLUSION: In DS rats fed a HS diet, nicorandil prevented the development of renal dysfunction, which was accompanied by an increase in eNOS expression in the kidneys.

Entities:  

Keywords:  NOx; Nicorandil; Oxidative stress; Salt-sensitive hypertensive nephropathy; eNOS

Mesh:

Substances:

Year:  2014        PMID: 24952900     DOI: 10.1007/s10157-014-0998-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  23 in total

1.  Impact of nicorandil in angina: subgroup analyses.

Authors: 
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

2.  Cortical tubular and glomerular dopamine receptors in the rat kidney.

Authors:  R A Felder; M Blecher; G M Eisner; P A Jose
Journal:  Am J Physiol       Date:  1984-05

3.  Nicorandil ameliorates ischaemia-reperfusion injury in the rat kidney.

Authors:  Shogo Shimizu; Motoaki Saito; Yukako Kinoshita; Fumiya Ohmasa; Fotios Dimitriadis; Kohei Shomori; Atsushi Hayashi; Keisuke Satoh
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

4.  Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats.

Authors:  Minoru Satoh; Yoshisuke Haruna; Sohachi Fujimoto; Tamaki Sasaki; Naoki Kashihara
Journal:  Hypertens Res       Date:  2009-11-20       Impact factor: 3.872

5.  Effect of nicorandil on proteinuria in well controlled hypertensive patients.

Authors:  Tsung-Ming Lee; Nen-Chung Chang
Journal:  J Hypertens       Date:  2009-03       Impact factor: 4.844

6.  Clinical potential of nicorandil to inhibit major cardiac events in hemodialysis patients with suspected myocardial ischemia.

Authors:  Masato Nishimura; Toshiko Tokoro; Masaya Nishida; Tetsuya Hashimoto; Hiroyuki Kobayashi; Satoru Yamazaki; Ryo Imai; Koji Okino; Noriyuki Iwamoto; Hakuo Takahashi; Toshihiko Ono
Journal:  Nephron Clin Pract       Date:  2009-02-19

7.  Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability.

Authors:  Ming-Sheng Zhou; Ivonne Hernandez Schuman; Edgar A Jaimes; Leopoldo Raij
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-07

8.  Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure.

Authors:  Dirk Westermann; Alexander Riad; Utz Richter; Sebastian Jäger; Konstantinos Savvatis; Mirjam Schuchardt; Nora Bergmann; Markus Tölle; Dirk Nagorsen; Michael Gotthardt; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Basic Res Cardiol       Date:  2009-03-03       Impact factor: 17.165

9.  Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.

Authors:  Katsuyuki Tanabe; Miguel A Lanaspa; Wataru Kitagawa; Christopher J Rivard; Makoto Miyazaki; Jelena Klawitter; George F Schreiner; Moin A Saleem; Peter W Mathieson; Hirofumi Makino; Richard J Johnson; Takahiko Nakagawa
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-15

10.  Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats.

Authors:  Ken-ichi Serizawa; Kenji Yogo; Ken Aizawa; Yoshihito Tashiro; Nobuhiko Ishizuka
Journal:  Cardiovasc Diabetol       Date:  2011-11-23       Impact factor: 9.951

View more
  5 in total

1.  Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.

Authors:  Yanming Fan; Qingmin Wei; Junna Cai; Yongtang Shi; Youliang Zhang; Limei Yao; Xiaogang Wang; Shupo Lin; Yilin Li; Jing Lv; Bin Zhou; Ruijuan Du
Journal:  Heart Vessels       Date:  2016-02-13       Impact factor: 2.037

2.  Anti-hypertensive effect of Lycium barbarum L. with down-regulated expression of renal endothelial lncRNA sONE in a rat model of salt-sensitive hypertension.

Authors:  Xinyu Zhang; Xinping Yang; Yahui Lin; Miaomiao Suo; Ling Gong; Jingzhou Chen; Rutai Hui
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

3.  Neuronal and Endothelial Nitric Oxide Synthases in the Paraventricular Nucleus Modulate Sympathetic Overdrive in Insulin-Resistant Rats.

Authors:  Qing-Bo Lu; Xue-Mei Feng; Ning Tong; Hai-Jian Sun; Lei Ding; Yu-Jiao Wang; Xuan Wang; Ye-Bo Zhou
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

4.  Nitric oxide and oxidative stress pathways do not contribute to sex differences in renal injury and function in Dahl SS/Jr rats.

Authors:  Hannah R Turbeville; Ashley C Johnson; Michael R Garrett; Elena L Dent; Jennifer M Sasser
Journal:  Physiol Rep       Date:  2020-07

Review 5.  Hypothesis: The potential therapeutic role of nicorandil in COVID-19.

Authors:  Hend Ashour; Mohamed H Elsayed; Soha Elmorsy; Inas A Harb
Journal:  Clin Exp Pharmacol Physiol       Date:  2020-09-09       Impact factor: 2.963

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.